COG Sessions

Saturday, October 30

11:30 am – 12:30 pm

Clinical Trials in the Children’s Oncology Group: A Case Study Approach (C229)

coglogoClinical trials are essential in the treatment of pediatric and young adult patients with cancer and have resulted in dramatic improvements in cure rates over the years. Because of clinical trials, we are now better able to understand the biology of different types of cancers affecting children and young adults and determine the best treatment options.

11:30 am – 12:30 pm

Paper Presentation: Program Development — Building a Sustainable and Structured Continuing Education Program for Pediatric Oncology Nurses in Vietnam (228-3)

There is a lack of continuing education opportunities for oncology nurses at the 13 pediatric cancer treatment centers in Vietnam. This presentation will discuss how nurses from the United States, Singapore, and Vietnam collaborated to develop an in-country, web-based educational program utilizing a variety of virtual teaching strategies.

11:30 am – 12:30 pm

Paper Presentation: Program Development — When Two Become One: Joining Two Programs to Promote Family-Centered Care for Pediatric Patients Undergoing Bone Marrow Transplantation (228-2)

Transplants often require families to be away from family and support networks for long periods of time. Patients are often acutely ill and require specialized care. Because of the complexity of treatment and the potential for complications, transplant is stressful and challenging for patients and their caregivers. To cope with this stress, many families rely on supportive systems, including family and friends.

11:30 am – 12:30 pm

Paper Presentation: Program Development — Nursing Practice Advocate: An Innovative Role Created to Reduce Harm While Supporting and Engaging Bedside Nursing Staff (228-1)

In 2019, inpatient pediatric hematology/oncology (PHO) and stem cell transplant (SCT) units within a children’s hospital experienced an increase in central line–associated bloodstream infections (CLABSIs) and mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBIs).